{"classes":[{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual titer value for this single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were further tested in screening assay, and positive samples were further characterized for antibody titers.","dispersionType":"Full Range","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 0.5 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28. Along with 4 mg Pomalidomide orally per day (QD) on Days 1-21 of each 28-day cycle and Dexamethasone 40mg (20 mg for participants \\>75 years old or BMI \\<18.5 kg/m\\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Safety population. Only those participants with positive post-baseline antibody against belantamab mafodotin were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 137 weeks","title":"DE Phase: Titer of ADAs Against Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"Titer"}